

## Clear Cell Sarcoma (CCS) Project Update

January 2020



### Researching Drug Hits for Clear Cell Sarcoma

Our CCS-focused drug screen included over 60 agents with potential activity for CCS. The agents were tested against a panel of CCS cell lines as well as normal (non-cancerous) cell lines. We are happy to report that multiple drug classes show promising activity for CCS. This chemical screen lays the foundation for selective agent testing so that we can correlate specific drug classes with identifiable markers associated with CCS and ultimately develop *effective* combination treatment strategies.

### Researching Secondary Mutations for Clear Cell Sarcoma

Thanks to generous pilot funding from Sara's Cure, we were able to sequence multiple CCS cell lines and human tumor samples. Samples were processed for DNA and RNA sequencing in order to learn more about key mutations that may play a role in CCS. We have been working closely with our bioinformatics team at Omics Data Automation to thoroughly analyze the data. Significant findings will be presented in our upcoming manuscript (discussed below). We likely need to sequence more patients' tumors, which will require writing a new grant to cover the additional cost.

### CCS Genomic Landscape Manuscript

Our first CCS genomic landscape manuscript is currently being written. We have decided to include a few additional experiments than originally planned to shed light on some of our more recent findings.

### Invitation to Present at FORTRESS 2020

Dr. Charles Keller (cc-TDI Scientific Director) has been invited to attend the FORum For Translational Research in SarcomaS (FORTRESS) meeting this January. FORTRESS 2020 is a new international, academic, not-for profit scientific meeting purely focused on translational research in sarcomas. Dr. Keller will be presenting cc-TDI's progress on CCS as well as establishing new global collaborations for initiatives on advancing CCS translational research in collaboration with EORTC investigators Dr. Patrick Schöffski and Dr. Agnieszka Wozniak.

### CureFAST Program at cc-TDI

Through CureFAST, we enrolled a new patient into our program and the team at cc-TDI was able to create a primary cell culture from this donated tissue. This cell culture was included in our chemical screening studies (results will be published in our upcoming manuscript). This cell line will also be immortalized and maintained as a new CCS cell line available for future research, facilitating further studies on the biology and treatment of CCS. As a reminder, we are actively enrolling patients into our CuRe-FAST Program, whereby tumor samples can be donated to cc-TDI and used for research purposes, free of charge. Please contact Andy Woods ([andy@cc-tdi.org](mailto:andy@cc-tdi.org)) for more information and to enroll.

### Fundraising

A special thanks to Sara's Cure and all of their donors for continued and on-going efforts dedicated to funding CCS-focused research at cc-TDI!